HK1047082B - 醚化合物,及其組合物和用途 - Google Patents
醚化合物,及其組合物和用途Info
- Publication number
- HK1047082B HK1047082B HK02108505.9A HK02108505A HK1047082B HK 1047082 B HK1047082 B HK 1047082B HK 02108505 A HK02108505 A HK 02108505A HK 1047082 B HK1047082 B HK 1047082B
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- compounds
- useful
- methods
- ether compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/04—Saturated ethers
- C07C43/13—Saturated ethers containing hydroxy or O-metal groups
- C07C43/132—Saturated ethers containing hydroxy or O-metal groups both carbon chains being substituted by hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12732199P | 1999-04-01 | 1999-04-01 | |
PCT/US2000/008788 WO2000059855A1 (en) | 1999-04-01 | 2000-03-31 | Ether compounds, compositions, and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
HK1047082A1 HK1047082A1 (en) | 2003-02-07 |
HK1047082B true HK1047082B (zh) | 2008-06-06 |
Family
ID=22429489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK02108505.9A HK1047082B (zh) | 1999-04-01 | 2002-11-25 | 醚化合物,及其組合物和用途 |
Country Status (13)
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0009520A (pt) * | 1999-04-01 | 2002-06-11 | Esperion Therapeutics Inc | Composto, método para sintetizar o mesmo, composição, metódos para o tratramento ou prevenção, em um paciente, de doença cardiovascular, dislipidemia, dislipoproteinemia, distúrbio de metabolismo de glucose, doença de alzheimer, sìndrome x ou sìndrome metabólica, septicemia, distúrbio trombótico, distúrbio associado com receptor ativado por proliferador de peroxissoma, obesidade, pancreatite, hipertensão, doença renal, câncer, inflamação, impotência, para reduzir o teor de gordura de carne de gado bovino, e, para reduzir o teor de colesterol de ovos de aves |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US20020127263A1 (en) * | 2001-02-27 | 2002-09-12 | Wenda Carlyle | Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device |
US20030225123A1 (en) * | 2001-03-22 | 2003-12-04 | Auerbach Bruce Jeffrey | Antihypertensive agents and use |
AU2002244732A2 (en) * | 2001-05-01 | 2002-11-11 | Gerhard Kamil | Application of fluid bed technology in brewing |
EP1438060B1 (en) * | 2001-09-28 | 2015-11-11 | Esperion Therapeutics Inc. | Prevention and treatment of restenosis by local administration of drug |
US20030170223A1 (en) * | 2002-02-01 | 2003-09-11 | Board Of Trustees Of Michigan State University | Pulmonary vasodilator surfactant compositions and method of use |
JP4025102B2 (ja) * | 2002-03-18 | 2007-12-19 | 富士フイルム株式会社 | ポジ型レジスト組成物 |
US20040009216A1 (en) * | 2002-04-05 | 2004-01-15 | Rodrigueza Wendi V. | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
AU2003230918A1 (en) * | 2002-04-10 | 2003-10-27 | Esperion Therapeutics, Inc. | Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses |
US20040148013A1 (en) * | 2002-04-18 | 2004-07-29 | Epstein Stephen E | Stent-based delivery statins to prevent restenosis |
GB0209539D0 (en) * | 2002-04-26 | 2002-06-05 | Avecia Ltd | Monomer Polymer and process |
US20040029941A1 (en) * | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
EP2301537A1 (en) * | 2002-05-17 | 2011-03-30 | Duke University | Zonisamide for the treatment of obesity |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
MXPA05000050A (es) * | 2002-07-03 | 2005-04-08 | Esperion Therapeutics Inc | Composiciones farmaceuticas y metodos para tratar, prevenir y manejar el colesterol, dislipidemia y enfermedades relacionadas. |
US20040220190A1 (en) * | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
US20040048910A1 (en) * | 2002-08-22 | 2004-03-11 | Bove Susan Elizabeth | Method of treating osteoarthritis |
MXPA05004992A (es) * | 2002-11-15 | 2005-08-02 | Warner Lambert Co | Metodo para rebajar crp y reducir la inflamacion sistemica. |
CA2513660C (en) | 2003-01-23 | 2012-05-08 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
SI2316456T1 (sl) * | 2003-04-29 | 2017-10-30 | Orexigen Therapeutics, Inc. | Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion |
WO2005002557A1 (en) * | 2003-07-03 | 2005-01-13 | Warner-Lambert Company Llc | Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof |
US20050074488A1 (en) * | 2003-07-28 | 2005-04-07 | Joel Melnick | Use of vitamin Ds to down regulate the renin-angiotensin-aldosterone system |
US20050148557A1 (en) * | 2003-07-29 | 2005-07-07 | Jin Tian | Use of Vitamin Ds to treat kidney disease |
US20060171983A1 (en) * | 2003-07-30 | 2006-08-03 | Jin Tian | Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease |
ATE428411T1 (de) * | 2003-11-07 | 2009-05-15 | Jj Pharma Inc | Hdl-verstärkende kombinationstherapie-komplexe |
AU2003300438A1 (en) * | 2003-12-24 | 2005-08-03 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
WO2005070461A2 (en) | 2004-01-13 | 2005-08-04 | Duke University | Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
TWI297606B (en) * | 2004-01-16 | 2008-06-11 | Nat Health Research Institutes | Cancer therapy |
US20050215558A1 (en) * | 2004-03-25 | 2005-09-29 | Cincotta Anthony H | Methods of identifying responders to dopamine agonist therapy |
US8137993B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
US8137994B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
EP1732383A4 (en) * | 2004-04-06 | 2007-05-02 | Cedars Sinai Medical Center | PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH VIRUS VECTORS ASSOCIATED WITH RECOMBINANT ADENOVIRUS CODING APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO |
US20060100205A1 (en) * | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
CN1968692A (zh) * | 2004-05-03 | 2007-05-23 | 杜克大学 | 影响体重减轻的组合物 |
KR20070043711A (ko) * | 2004-06-09 | 2007-04-25 | 아바니르 파마슈티컬스 | 고콜레스테롤혈증과 관련 질환의 치료를 위한 소분자 |
CA2568394A1 (en) * | 2004-06-09 | 2005-12-29 | Avanir Pharmaceuticals | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases |
TW200603795A (en) * | 2004-06-09 | 2006-02-01 | Avanir Pharmaceuticals | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
MX2007013430A (es) | 2005-04-29 | 2008-03-19 | Univ California | Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria. |
EP2135603B1 (en) * | 2005-11-22 | 2013-01-02 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
TW200803901A (en) * | 2005-11-28 | 2008-01-16 | Orexigen Therapeutics Inc | Methods of treating anxiety disorders |
CA2653840A1 (en) * | 2006-06-01 | 2007-12-06 | Institut De Cardiologie De Montreal | Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
CA2659655A1 (en) | 2006-08-08 | 2008-02-21 | Alan M. Fogelman | Salicylanilides enhance oral delivery of therapeutic peptides |
WO2008018877A1 (en) | 2006-08-11 | 2008-02-14 | Ssv Therapeutics, Inc. | Carnitine conjugates as dual prodrugs, methods of production and uses thereof |
CA2666846C (en) | 2006-10-20 | 2018-04-10 | Cpd, Llc | Method of restoring the incretin effect |
EA017713B1 (ru) * | 2006-11-01 | 2013-02-28 | Байер Шеринг Фарма Акциенгезельшафт | [f-18]-меченая l-глутаминовая кислота, [f-18]-меченый l-глутамин, их производные и их применение, а также способ их получения |
KR20150082689A (ko) * | 2006-11-09 | 2015-07-15 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
KR101735466B1 (ko) | 2006-11-09 | 2017-05-15 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
EP2167069B1 (en) | 2007-05-23 | 2011-10-26 | Amcol International Corporation | Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal |
US20090004056A1 (en) * | 2007-06-26 | 2009-01-01 | Dade Behring Inc. | Clinical Sample Analysis System Having An Analyzer Positioning Mechanism |
DK2180787T3 (da) | 2007-08-01 | 2014-02-03 | Univ Pittsburgh | Nitrooliesyremodulering af type ii-diabetes |
CA2697957A1 (en) | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
DK2682400T5 (da) | 2007-08-28 | 2017-11-27 | Uab Research Foundation | Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse |
US7985727B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Apo A-I mimetic peptides and methods of treatment |
US8101565B2 (en) * | 2007-09-20 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
US9173890B2 (en) * | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
US8044021B2 (en) * | 2007-09-20 | 2011-10-25 | Abbott Cardiovascular Systems Inc. | Sustained release of apo A-I mimetic peptides and methods of treatment |
US7985728B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
DK2280928T3 (en) | 2008-05-01 | 2018-11-05 | Complexa Inc | Vinyl-substituted fatty acids |
CA2725930A1 (en) * | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
WO2009155439A2 (en) | 2008-06-19 | 2009-12-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
CA2788223A1 (en) | 2009-01-23 | 2010-07-29 | Institut De Cardiologie De Montreal | Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex |
SI2396017T1 (sl) | 2009-02-16 | 2015-12-31 | Cerenis Therapeutics Holding Sa | Mimika apolipoproteina A-1 |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
CA2769624C (en) | 2009-07-31 | 2018-09-11 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Electrophilic fatty acid derivatives as anti-inflammatory agents |
AU2010290931B2 (en) | 2009-09-03 | 2014-02-06 | Pfizer Vaccines Llc | PCSK9 vaccine |
EP2483233A4 (en) * | 2009-10-02 | 2013-08-14 | Complexa Inc | HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS |
CN102724878A (zh) * | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
WO2011143362A1 (en) | 2010-05-11 | 2011-11-17 | Esperion Therapeutics, Inc. | Dimeric oxidation-resistant apolipoprotein a1 variants |
ES2608177T3 (es) | 2010-12-27 | 2017-04-06 | Gemphire Therapeutics Inc. | Gemcabeno y derivados para el tratamiento de la pancreatitis |
AU2015202580B2 (en) * | 2010-12-27 | 2016-06-16 | Gemphire Therapeutics Inc. | Gemcabene and derivatives for treating pancreatitis |
US20140004142A1 (en) | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
WO2013028501A1 (en) | 2011-08-19 | 2013-02-28 | The University Of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
EP3735967A1 (en) | 2012-01-06 | 2020-11-11 | NeuroBo Pharmaceuticals, Inc. | Compound for use in methods of reducing risk of cardiovascular disease |
DK3730132T3 (da) | 2012-06-06 | 2022-08-08 | Nalpropion Pharmaceuticals Llc | Sammensætning til anvendelse ved en fremgangsmåde til behandling af overvægt og obesitas hos patienter med høj kardiovaskulær risiko |
US10279019B2 (en) | 2014-02-11 | 2019-05-07 | Stc.Unm | PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same |
WO2015173633A2 (en) | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
WO2016018665A1 (en) | 2014-07-31 | 2016-02-04 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
WO2016073615A1 (en) | 2014-11-07 | 2016-05-12 | Regents Of The University Of Minnesota | Salts and compositions useful for treating disease |
CA2966631A1 (en) | 2014-11-14 | 2016-05-19 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing alpha, omega-dicarboxylic acid-terminated dialkane ethers |
CN107530307A (zh) | 2015-03-13 | 2018-01-02 | 艾斯柏伦治疗公司 | 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法 |
MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
TN2017000507A1 (en) | 2015-07-07 | 2019-04-12 | H Lundbeck As | Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
US20170031954A1 (en) * | 2015-07-27 | 2017-02-02 | Alexandre PESTOV | Image association content storage and retrieval system |
CA3000842A1 (en) | 2015-10-02 | 2017-04-06 | Complexa, Inc. | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
CN105801405A (zh) * | 2016-05-23 | 2016-07-27 | 天津迪尔斯化学科技有限公司 | 一种降血脂小分子化合物、中间体及各自制备方法 |
EP3765435A1 (en) * | 2018-03-14 | 2021-01-20 | Universiteit Antwerpen | Long alpha-omega di-functional linear ethers |
US11434353B2 (en) | 2019-02-12 | 2022-09-06 | Appia, Llc | Method and product of modifying vulcanized rubber |
CA3144371A1 (en) | 2019-06-21 | 2020-12-24 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
CA3143294A1 (en) | 2019-07-26 | 2021-02-04 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease |
KR20230152007A (ko) | 2021-01-25 | 2023-11-02 | 에스퍼비타 테라퓨틱스, 인크. | 작용화된 장쇄 카복실산, 및 질환의 치료를 위한 이의 용도 |
US11730712B2 (en) | 2021-01-25 | 2023-08-22 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease |
CN113999091A (zh) * | 2021-11-30 | 2022-02-01 | 南通宝凯药业有限公司 | 一种双(4-氯丁基)醚的制备方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3152148A (en) | 1963-01-03 | 1964-10-06 | Dow Chemical Co | Preparation of comenic and pyromeconic acids |
GB1269658A (en) | 1968-07-29 | 1972-04-06 | Upjohn Co | Improvements in or relating to prostaglandins and the manufacture thereof |
IL32518A (en) * | 1968-07-29 | 1974-03-14 | Upjohn Co | Prostaglandins and analogs thereof |
US3930024A (en) | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
US3773946A (en) | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
JPS6022708B2 (ja) * | 1977-07-14 | 1985-06-03 | 小野薬品工業株式会社 | プロスタグランジン類似化合物 |
JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5639033A (en) | 1979-09-04 | 1981-04-14 | Kao Corp | Alpha-mono(methyl-branched alkyl glyceryl ether and skin cosmetic containing the same |
IL64542A0 (en) | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
IT1164254B (it) * | 1983-05-30 | 1987-04-08 | Luso Farmaco Inst | 3-(3-idrossibutossi)-1-butanolo e suo metodo di preparazione |
JPS60136512A (ja) | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 脂質代謝改善剤 |
DE3423166A1 (de) | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
US4714762A (en) | 1986-10-31 | 1987-12-22 | Warner-Lambert Company | Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof |
US5225439A (en) | 1987-01-28 | 1993-07-06 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
CA1323364C (en) | 1987-01-28 | 1993-10-19 | Ryuzo Ueno | Prostaglandins e and anti ulcer agents containing same |
US5428062A (en) | 1987-01-28 | 1995-06-27 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
GB8717435D0 (en) | 1987-07-23 | 1987-08-26 | Easibind Ltd | Fastening device |
US5468755A (en) * | 1988-05-10 | 1995-11-21 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of Type II diabetes |
JP2999579B2 (ja) | 1990-07-18 | 2000-01-17 | 武田薬品工業株式会社 | Dnaおよびその用途 |
DE4416447C1 (de) | 1994-05-10 | 1995-08-24 | Aqua Medic Anlagenbau Gmbh | Eiweißabschäumer |
US5447922A (en) * | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
IL119971A (en) | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
IL121165A0 (en) | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6184422B1 (en) * | 1998-02-26 | 2001-02-06 | Hoffman-La Roche Inc. | Cyclohexanediol derivatives |
BR0009520A (pt) * | 1999-04-01 | 2002-06-11 | Esperion Therapeutics Inc | Composto, método para sintetizar o mesmo, composição, metódos para o tratramento ou prevenção, em um paciente, de doença cardiovascular, dislipidemia, dislipoproteinemia, distúrbio de metabolismo de glucose, doença de alzheimer, sìndrome x ou sìndrome metabólica, septicemia, distúrbio trombótico, distúrbio associado com receptor ativado por proliferador de peroxissoma, obesidade, pancreatite, hipertensão, doença renal, câncer, inflamação, impotência, para reduzir o teor de gordura de carne de gado bovino, e, para reduzir o teor de colesterol de ovos de aves |
EP1363879A2 (en) * | 2000-10-11 | 2003-11-26 | Esperion Therapeutics Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
-
2000
- 2000-03-31 BR BR0009520-6A patent/BR0009520A/pt not_active Application Discontinuation
- 2000-03-31 CN CNA200710126412XA patent/CN101165036A/zh active Pending
- 2000-03-31 US US09/540,740 patent/US6410802B1/en not_active Expired - Fee Related
- 2000-03-31 CN CNB008083223A patent/CN1329359C/zh not_active Expired - Fee Related
- 2000-03-31 WO PCT/US2000/008788 patent/WO2000059855A1/en active IP Right Grant
- 2000-03-31 US US09/540,739 patent/US6506799B1/en not_active Expired - Fee Related
- 2000-03-31 CA CA2369074A patent/CA2369074C/en not_active Expired - Fee Related
- 2000-03-31 IL IL14571200A patent/IL145712A0/xx unknown
- 2000-03-31 JP JP2000609370A patent/JP2002541129A/ja not_active Withdrawn
- 2000-03-31 AU AU41901/00A patent/AU779784B2/en not_active Ceased
- 2000-03-31 AT AT00921608T patent/ATE384035T1/de not_active IP Right Cessation
- 2000-03-31 EP EP00921608A patent/EP1204626B1/en not_active Expired - Lifetime
- 2000-03-31 MX MXPA01009893A patent/MXPA01009893A/es active IP Right Grant
- 2000-03-31 DE DE60037818T patent/DE60037818D1/de not_active Expired - Lifetime
- 2000-03-31 US US09/540,738 patent/US6459003B1/en not_active Expired - Fee Related
-
2002
- 2002-04-26 US US10/132,914 patent/US6646170B2/en not_active Expired - Fee Related
- 2002-07-26 US US10/205,939 patent/US6790953B2/en not_active Expired - Fee Related
- 2002-11-25 HK HK02108505.9A patent/HK1047082B/zh not_active IP Right Cessation
- 2002-11-26 US US10/305,440 patent/US6831105B2/en not_active Expired - Fee Related
-
2003
- 2003-09-05 US US10/656,974 patent/US6909014B2/en not_active Expired - Fee Related
-
2004
- 2004-07-16 US US10/893,791 patent/US7192940B2/en not_active Expired - Fee Related
- 2004-11-16 US US10/990,304 patent/US7709515B2/en not_active Expired - Fee Related
-
2006
- 2006-10-31 IL IL178952A patent/IL178952A0/en unknown
-
2009
- 2009-10-15 US US12/579,752 patent/US20100256209A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL145712A0 (en) | Ether compounds, compositions, and uses thereof | |
WO2002030863A3 (en) | Ether compounds and compositions for cholesterol management and related uses | |
WO2002030860A3 (en) | Ketone compounds and compositions for cholesterol management and related uses | |
WO2002030884A3 (en) | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | |
WO2002030882A3 (en) | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses | |
MXPA05007674A (es) | Compuestos de hidroxilo y composiciones para el manejo del colesterol y usos relacionados. | |
ATE169498T1 (de) | Zusammensetzung, die eine tramadol-verbindung und acetaminophen enthält, und ihre verwendung | |
TR199900293T2 (xx) | Alzheimer hastal��� tedavisi i�in bir farmas�tik bile�im �retmek �zere �elat maddesi clioquil'un kullan�m�. | |
LT2003002A (en) | A soluble ctla4 molecule for use in the treatment rheumatic diseases | |
AP2000001929A0 (en) | Substituted indolealkanoic acids. | |
BG103740A (en) | Phytostyrene composition for the prevention of the alzheimer's disease | |
EG20041A (en) | Composition comprising a tramadol material and non-steroidal anti-inflammatory durg | |
BRPI0207700B8 (pt) | mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero | |
MY137768A (en) | Rapidly disintegrating methylcellulose tablets | |
AP2001002377A0 (en) | Substituted phenoxyacetic acids. | |
WO2003087108A3 (en) | Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses | |
IL159241A0 (en) | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | |
KR960030947A (ko) | src SH2 특이성 화합물의 골흡수 질환 치료 용도 | |
EP1862444A3 (en) | Ether compounds, compositions, and uses thereof | |
BG104062A (en) | Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor | |
DE69619543T2 (de) | Carbonyleisen-tablette durch direktverpressung | |
MXPA05003633A (es) | 2"-oxo-voruscharina y derivados de la misma. | |
MY138338A (en) | Substituted indolealkanoic acids | |
EP1408043A8 (en) | 2''oxo-voruscharin and analogues thereof | |
MY114755A (en) | Composition comprising a tramadol material and acetaminophen and its use. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20120331 |